In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Alan Roth, CEO of Oxford Drug Design, about the use ...
AI takes centre stage at an EMBO workshop exploring emerging trends, collaborative opportunities, and recent advances in computational structural ...
Discovering effective drug combinations may now be easier thanks to a screening platform made public today by St. Jude ...
Less than six months after a series A fundraise, AI drug developer Chai Discovery has brewed up a $130 million series B to ...
A Seattle-area startup called Pauling.AI is harnessing artificial intelligence to automate the early steps that lead to the ...
AlphaFold didn't accelerate biology by running faster experiments. It changed the engineering assumptions behind protein ...
Parasitic diseases pose an ongoing scientific and clinical challenge, especially when it comes to neglected pathogens such as Trypanosoma cruzi, Leishmania ...
Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules, today announced its $130 million Series B financing round co-led by Oak HC/FT and General ...
ProFound™ Therapeutics, a Flagship Pioneering company pioneering the expanded human proteome to develop first-in-class ...
Mo Khalil is the Hok Lam and Kathleen Kam Wong Professor of Bioengineering and Professor of Molecular and Cellular Biology at ...
CatDRX is a generative AI framework developed at Institute of Science Tokyo, which enables the design of new chemical ...
A monkeypox vaccine or antibody therapy may have taken a step closer to reality, as AI reveals new drug target.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback